Research
Hormonal
Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).
Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.
StrongSupportsmedium confidence
Clinically significant RGV occurred in 3.1% in the hold group vs 25.0% in the continue group (absolute difference, 21.9% [90% CI, 7.0%-36.7%]; P = .003).
Why this rating
Based on a randomized clinical trial design.
Source
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Akram I. Ahmad et al. · JAMA Internal Medicine · 2026
DOI 10.1001/jamainternmed.2026.0027
rct · n=60Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →